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Abstract
Loss of the tumor suppressor Pdcd4 was reported for various tumor entities and proposed as a prognostic marker in
tumorigenesis. We previously characterized decreased Pdcd4 protein stability in response to mitogenic stimuli, which
resulted from p70
S6K1-dependent protein phosphorylation, b-TrCP1-mediated ubiquitination, and proteasomal destruction.
Following high-throughput screening of natural product extract libraries using a luciferase-based reporter assay to monitor
phosphorylation-dependent proteasomal degradation of the tumor suppressor Pdcd4, we succeeded in showing that a
crude extract from Eriophyllum lanatum stabilized Pdcd4 from TPA-induced degradation. Erioflorin was identified as the
active component and inhibited not only degradation of the Pdcd4-luciferase-based reporter but also of endogenous Pdcd4
at low micromolar concentrations. Mechanistically, erioflorin interfered with the interaction between the E3-ubiquitin ligase
b-TrCP1 and Pdcd4 in cell culture and in in vitro binding assays, consequently decreasing ubiquitination and degradation of
Pdcd4. Interestingly, while erioflorin stabilized additional b-TrCP-targets (such as IkBa and b-catenin), it did not prevent the
degradation of targets of other E3-ubiquitin ligases such as p21 (a Skp2-target) and HIF-1a (a pVHL-target), implying
selectivity for b-TrCP. Moreover, erioflorin inhibited the tumor-associated activity of known Pdcd4- and IkBa-regulated
atranscription factors, that is, AP-1 and NF-kB, altered cell cycle progression and suppressed proliferation of various cancer
cell lines. Our studies succeeded in identifying erioflorin as a novel Pdcd4 stabilizer that inhibits the interaction of Pdcd4
with the E3-ubiquitin ligase b-TrCP1. Inhibition of E3-ligase/target-protein interactions may offer the possibility to target
degradation of specific proteins only as compared to general proteasome inhibition.
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Introduction
Programmed cell death 4 (Pdcd4) is a novel tumor suppressor
that inhibits translation rather than transcription. Specifically,
Pdcd4 interferes with the activity of the eukaryotic initiation
factor (eIF) 4A by displacing the scaffold protein eIF4G from its
binding to the RNA helicase eIF4A [1]. As a consequence,
Pdcd4 attenuates neoplastic transformation, AP-1 transactiva-
tion, intravasation, and invasion in vitro [2,3]. In addition,
Pdcd4-deficient mice were shown to be more susceptible to the
two stage skin carcinogenesis model, whereas transgenic
overexpression of Pdcd4 decreased papilloma incidence and
multiplicity [4,5]. In line, Pdcd4 is lost in various tumor entities
such as lung, colon, breast, ovarian and pancreatic cancer [6,7].
Interestingly, loss of Pdcd4 appears not to be attributable to
mutational inactivation [8]. Instead, post-transcriptional regula-
tory mechanisms appear to control Pdcd4 expression in tumors.
Specifically, in addition to miR-21-dependent repression of
Pdcd4 expression [9,10], increased proteasomal degradation was
recently identified to determine Pdcd4 levels in response to
mitogens and inflammatory tumor environments [5,11,12].
Mechanistically, Pdcd4 protein contains a p70
S6K1 consensus
phosphorylation sequence directly followed by the binding motif
for the E3-ubiquitin ligase b-transducin repeat-containing
protein (b-TrCP). Activation of p70
S6K1 in response to mitogens
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(TPA) results in phosphorylation of Pdcd4, followed by binding
of b-TrCP, polyubiquitination and subsequent proteasomal
degradation [5,11]. Overactivation of the PI3K-Akt-mTOR-
p70
S6K axis is common in many tumor types [13]. Conse-
quently, interference with this signaling cascade is widely used
for current tumor therapeutic regimens, e.g. mTOR inhibitors
are in clinical use for the treatment of renal cell carcinomas and
mantle-cell lymphomas [14].
The E3-ubiquitin ligase b-TrCP represents the substrate
recognition subunit of the SCF (Skp1-Cul1-FBP) ligase complex
that transfers ubiquitin molecules to label target-proteins for
proteasomal degradation [15]. Despite the high diversity in
reported b-TrCP-targets, including tumor suppressive (e.g. IkBa)
and oncogenic factors (e.g. b-catenin), b-TrCP is considered an
oncoprotein [16]. In line, cancer tissues are often associated
with elevated b-TrCP levels [17]. Furthermore, b-TrCP-
deficient cells were shown to be more sensitive to various
anti-cancer drugs such as doxorubicin, tamoxifen and paclitaxel
[18]. Targeting the ubiquitin proteasome system (UPS) for
tumor therapeutic purposes was proven to be a promising
approach by the introduction of the general proteasome
inhibitor velcade (bortezomib) for the treatment of multiple
myeloma [19]. As expected, the unselective inhibition of protein
degradation causes adverse side effects, limiting the use of such
an approach. Since substrate specificity of the UPS is achieved
by the E3-ligases, this class of proteins offers a novel avenue for
tumor therapies. To date, the only compounds targeting an E3-
ubiquitin ligase in clinical trials are substances of the nutlin
family that disrupt the Hdm2-p53 binding and, thus prevent
Hdm2-induced p53 degradation [20]. Accordingly, attenuating
the interaction of b-TrCP with its target-proteins could be a
promising approach for the development of proteasomal
degradation targeting drugs for tumor therapies. Stabilization
of the b-TrCP-target Pdcd4 provides an attractive tool for the
identification of novel b-TrCP-inhibitors, which might be
further developed for use in anti-tumor therapies.
Therefore, we set out to identify novel stabilizers of the tumor
suppressor Pdcd4, which interfere specifically with b-TrCP-
mediated degradation of Pdcd4.
Materials and Methods
Materials
All chemicals were purchased from Sigma-Aldrich unless noted
otherwise. Rapamycin and TPA (12-O-tetradecanolyphorbol-13-
acetate) were from LC Laboratories. Anti-Pdcd4, anti-phospho-
S6, anti-b-TrCP and anti-b-catenin antibody were obtained from
Cell Signaling Technology. Anti-luciferase antibody came from
Promega, anti-nucleolin and anti-IkB antibody from Santa Cruz
Biotechnology, anti-HIF-1a and anti-p21 antibody were from BD
Biosciences. IRDyes 680LT and 800CM secondary antibodies
were purchased from Li-COR Biosciences GmbH and horseradish
peroxidase (HRP)-coupled secondary antibodies came from GE
Healthcare. Blasticidin and recombinant p70
S6K1 were from
Invitrogen. Protease and phosphatase inhibitor mix were obtained
from Roche. pRK7-S6K expression plasmids were kindly provid-
ed by J. Blenis. pcDNA3-b-TrCP1 was kindly provided by M.
Pagano. AP-1 and NF-kB reporter plasmids were previously
described [21,22]. pGL3-Pdcd4(39–91)luc was previously described
[23]. pRL-TK expression vector for renilla luciferase was from
Promega.
Cloning of Pdcd4 Constructs and Generation of Stable
Cell Lines
For the generation of phosphorylation insensitive Pdcd4
constructs, serines 67, 71 and 76 were mutated to alanines in
Figure 1. Erioflorin stabilizes Pdcd4(39–91)luc from TPA-induced
degradation. (A) Structure of erioflorin (Mwt=348.4). (B) Stably
Pdcd4(39–91)luc expressing HEK293 cells were treated for 8 h with TPA
(10 nM) with increasing concentrations of erioflorin (0.0625–10 mM).
Pdcd4 stabilizing activity was determined relative to D(RLUcontrol–
RLUTPA-only). (C) Stably Pdcd4(mut39–91)luc expressing HEK293 cells were
treated as in (B). Luciferase activity is given relative to TPA-treated
controls. All data are presented as means 6 SEM (n$3, *p,0.05,
**p,0.01).
doi:10.1371/journal.pone.0046567.g001
Erioflorin Inhibits the Pdcd4/b-TrCP1 Interaction
PLOS ONE | www.plosone.org 2 October 2012 | Volume 7 | Issue 10 | e46567pcDNA3.1(+)-Pdcd4 plasmid [24] using the QuikChange kit
(Agilent Technologies, Waldbronn, Germany) according to the
manufacturer’s protocol. Reporter constructs for Pdcd4(39–91mu-
t)luc were generated as previously described for Pdcd4(39–91)luc
[23]. Briefly, a fragment of Pdcd4 (encoding amino acids 39–91)
was amplified from the mutated vector. HindIII and NarI
restriction sides were added to the Pdcd4-specific amplicons.
The resulting fragment was fused to the luciferase expression
cassette of the pGL3-control vector. The resulting Pdcd4(mut39–
91)luc vector was used for transient transfections. For generating
stable cell lines, EcoRI and BamHI restriction sides were
introduced into the Pdcd4(mut39–91)luc pGL3-vector by PCR
amplification and the resulting construct was inserted in a
modified pFB-neo plasmid where the neomycin cassette has been
replaced by a blasticidin resistance cassette. Stable cell lines were
created by retroviral gene transfer as described before [23]. All
sequences were confirmed by sequence analysis.
Cell Culture
All cell lines (HEK, MCF7, HeLa, RKO) came from LGC
Standard GmbH and were maintained in DMEM supplemented
with 10% fetal bovine serum (FBS), 100 U mL
–1 penicillin, 100 mg
mL
–1 streptomycin and 2 mM L-glutamine. HeLa cells were
maintained in MEM supplemented with 10% FBS, 100 U mL
–1
penicillin, 100 mgm L
–1 streptomycin and 2 mM L-glutamine.
Stable HEK293 Pdcd4-luc cells were maintained in regular
growth medium supplemented with 3 mgm L
–1 blasticidin. Cells
were cultivated in a humidified atmosphere with 5% CO2 at 37uC.
Medium and supplements came from PAA and FBS was
purchased from Biochrom.
Plant Material, Extraction, and Isolation
Samples of Eriophyllum lanatum var. grandiflorum (A. Gray) Jeps.
were collected on a bank below a coniferous forest 27 miles east of
Crescent City, CA in July 1997. The collection and identification
were done by William Hess, Morton Arboretum Herbarium, Lisle,
IL. A voucher specimen (collection number 0GDK760) is
maintained at the Smithsonian Institution. The dried plant
material (562 g) was ground and extracted by immersion in
CH2Cl2-MeOH (1:1) for 15 h in a Soxhlet apparatus [25]. The
solvent was removed and the plant material was immersed for
15 h in 100% MeOH. The combined extracts were reduced to
dryness in vacuo to give 36.8 g of crude extract. A portion of this
extract (1.54 g) was subjected to a solvent-solvent partitioning
scheme [26] that concentrated the Pdcd4 stabilizing activity in the
ethyl acetate soluble fraction (288 mg). Size exclusion chromatog-
raphy of this material on Sephadex LH-20 (2675 cm) eluted with
CH2Cl2-MeOH (1:1) provided five major fractions (A–E). Fraction
C (112 mg) was further purified by reversed-phase HPLC (Rainin;
Dynamax C18, size 21.46250 mm; 60 mm) eluting with a gradient
of 10–100% acetonitrile in 0.05% aqueous TFA over 40 min at a
flow rate of 8 mL min
–1. Final separation by reversed-phase
HPLC (Rainin; Dynamax C18, size 4.66250 mm; 60 mm) eluting
with a gradient of 20–40% acetonitrile in 0.05% aqueous TFA for
40 min at a flow rate of 1 mL/min provided 12.1 mg of erioflorin
(0.8% yield).
Assignment of the
1H-NMR Data of Erioflorin
1H-NMR (600 MHz, CDCl3) d 1.32 (1H, dd, J=1.6, 12.6 Hz,
H-9b), 1.44 (3H, s, H-14), 1.73 (1H, ddd, J=2.0, 8.5, 12.4 Hz, H-
2b), 1.80 (3H, d, J=0.75, H-15), 1.90 (3H, s, H-49), 2.45 (1H, dt,
J=3.7, 12.4 Hz, H-2a), 2.79 (1H, dd, J=3.7, 8.3 Hz, H-1), 2.81
(1H, dd, J=3.7, 12.6 Hz, H-9a), 2.87 (1H, m, H-7), 4.48 (1H, dd,
J=2.0, 3.7 Hz, H-3), 5.16 (1H, m, H-8), 5.31 (1H, dq, J=1.0,
9.1 Hz, H-5), 5.59 (1H, brs, H-39), 5.75 (1H, d, J=1.5 Hz, H-
13a), 6.09 (1H, brs, H-39), 6.35 (1H, d, J=1.5 Hz, H-13b ), 6.65
(1H, dd, J=1.6, 9.1 Hz, H-6); HREIMS m/z 349.1635 [M + H]
+
(Calcd for C19H25O6, 349.1646).
Luciferase Assays
HEK293 cells stably expressing either Pdcd4(39–91)luc or
Pdcd4(mut39–91)luc were seeded in a 96-well plate (1610
4/well)
and allowed to attach for 18 h before treatment. After incubations,
cells were harvested in firefly luciferase lysis buffer (25 mM Tris,
2 mM DTT, 1% Triton X 100, 10% glycerol, pH 7.8) and frozen
at –20uC for at least 2 h. After lysis at room temperature,
luminescence was measured using firefly luciferase substrate
solution (20 mM tricine, 2.67 mM 4MgCO3*Mg(OH)2*5H2O,
1.07 mM MgSO4*7H2O, 100 mM EDTA, 33.3 mM dithiothreitol
(DTT), 530 mM ATP, 0.213 mg mL
–1 coenzym A, 470 mM D-
luciferin) on a Mithras LB 940 (Berthold, Bad Wildbad, Germany).
p70
S6K expression plasmids were transiently co-transfected with
pGL3-Pdcd4(39–91)luc or pGL3-Pdcd4(mut39–91)luc and a renilla
luciferase reporter plasmid into HEK293 cells (1610
4) in 96-well
plates using the calcium phosphate precipitation method [27].
Briefly, plasmids were incubated for 15 min at room temperature
in the presence of 125 mM CaCl2 and HBS buffer (25 mM
HEPES, 140 mM NaCl, 0.75 mM Na2HPO4, 5 mM KCl,
pH 7.1) and added drop-wise to cells. Eight hours later medium
was changed and incubations were continued for another 16-h
period before cells were treated as indicated. Cells were lysed in
passive lysis buffer (Promega, Mannheim, Germany). Firefly
luciferase activity was determined as described above and renilla
luciferase activity was measured with renilla substrate solution
(0.1 M NaCl, 25 mM Tris-HCl pH 7.5, 1 mM CaCl2,1 mM
coelenterazine).
AP-1 and NF-kB reporter plasmids were transfected and
analysis was performed as described above.
Western Analysis
For western analysis, HEK293 cells (5610
5/6 cm-dish) were
treated as indicated, harvested by centrifugation in ice cold PBS
and lysed in lysis buffer (50 mM Tris-HCl pH 6.8, 5 mM EDTA,
6.65 M urea, 1% SDS, 10% glycerol, 1 mM phenylmethylsulfo-
nylfluoride (PMSF), 1 x protease and phosphatase inhibitor mix,
1m MN a 3VO4, 1 mM DTT). 80 mg protein were separated via
SDS-PAGE, transferred onto nitrocellulose membranes and
analyzed using specific antibodies with appropriate secondary
antibodies. They were visualized using either the Odyssey infrared
imaging system (Li-COR Biosciences GmbH) or enhanced
chemiluminescence detection.
Immunoprecipitation Assays
For immunoprecipitation assays, HEK293 cells (1610
6/10 cm-
dish) were transiently transfected with b-TrCP1 expression
plasmid or with a plasmid expressing HA-tagged ubiquitin as
described above. One day after transfection, cells were treated as
indicated. After treatment, cells were lysed on ice for 30 min in
immunoprecipitation (IP) buffer (50 mM Tris-HCl pH 7.4,
300 mM NaCl, 5 mM EDTA, 1% NP-40, 1 mM PMSF, 1 x
protease and phosphatase inhibitor mix, 1 mM Na3VO4). 1 mg
protein was incubated with either 5 mL anti-Pdcd4- or 5 mL anti-
luciferase-antibody in 300 mL IP buffer for 6 h. Then, 20 mL 50%
slurry of Protein A Sepharose (Sigma-Aldrich) were added and
incubated overnight. Sepharose was precipitated by centrifugation
and washed three times with IP buffer. Proteins were eluted by
addition of 2 x loading buffer and incubation at 95uC for 5 min.
Immunoprecipitated proteins were separated via SDS-PAGE and
Erioflorin Inhibits the Pdcd4/b-TrCP1 Interaction
PLOS ONE | www.plosone.org 3 October 2012 | Volume 7 | Issue 10 | e46567Figure 2. Erioflorin stabilizes Pdcd4 without affecting phosphorylation events. (A + B) HEK293 cells were transiently transfected with
Pdcd4(39–91)luc (A) or Pdcd4(mut39–91)luc (B) firefly reporter vectors, in combination with expression vectors for either wildtype (S6Kwt=white bars) or
constitutively active p70
S6K (S6Kca=black bars) and a renilla luciferase vector one day prior to the experiment. Transfected cells were treated for 8 h
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Whole cell extracts served as loading control and analysis was
performed as described above.
In Vitro-Transcription/Translation Assay
Pdcd4 and b-TrCP1 proteins were generated by in vitro-
transcription/translation from pcDNA3.1(+)-Pdcd4 and
pcDNA3-b-TrCP1, respectively, using the TNT Coupled Retic-
ulocyte Lysate System from Promega according to manufacturer’s
protocol. Interaction reactions were performed for 90 min at 30uC
in a volume of 15 mL containing 50 mM Tris-HCl pH 7.6, 5 mM
MgCl2, 2 mM ATP, 4 mL Pdcd4, 3 mL b-TrCP1 and 160 nM
recombinant p70
S6K1 as indicated. Immunoprecipitation and
western analyses were performed as described above.
Viability Assay
HEK293 cells (1610
4/well) were seeded in a 96-well plate and
allowed to attach for 18 h. Cells were treated as indicated and
viability was measured using the CellTiter-Glo Luminescent Cell
Viability Assay from Promega according to the manufacturer’s
protocol.
Proliferation Assay
RKO, HeLa and MCF7 cells (1610
4/well) were seeded in 96-
well plates one day prior to the experiment. Cells were treated as
with rapamycin (100 nM) or erioflorin (5 mM). Firefly normalized to renilla luciferase activity is presented relative to DMSO-treated controls. (C) HEK293
cells were treated for 8 h with TPA (10 nM) with or without erioflorin (0.625–5 mM). Whole-cell extracts were subjected to western analysis and
probed with the indicated antibodies. Blots are representative of at least three independent experiments. Densitometric analysis and quantification
of nucleolin-normalized Pdcd4 and phospho-S6 protein levels is shown relative to the DMSO control. (D) HEK293 cells were treated with DMSO (black
diamonds), TPA (10 nM) with (white triangles) or without (gray squares) erioflorin (5 mM) for 8 h and cycloheximide (10 mM) was added for 1, 2 or 4 h.
Pdcd4 protein levels were analyzed densitometrically, normalized to nucleolin and the half-life was calculated. All data are presented as means 6 SEM
(n$3, *p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0046567.g002
Figure 3. Erioflorin stabilizes Pdcd4 by interfering with b-TrCP1. (A) Stably Pdcd4(39–91)luc expressing or (B) wildtype HEK293 cells were
transfected with a b-TrCP1 expression vector one day prior to the experiment. Transfected cells were treated for 8 h with DMSO or TPA (10 nM) with
or without erioflorin (5 mM) in the presence of the proteasome inhibitor MG132 (10 mg mL
–1). Pull-down of luciferase (A) or Pdcd4 (B) out of whole-
cell extracts was performed using specific antibodies. Subsequently, immunoprecipitated (IP) proteins and whole cell extracts (WCE) were subjected
to western analysis and probed with the indicated antibodies. (C) In vitro-transcribed/translated b-TrCP1 and Pdcd4 proteins were co-incubated for
90 min at 30uC with or without recombinant p70
S6K1 in the absence or presence of erioflorin (5 mM). Pdcd4 protein was immunoprecipitated and b-
TrCP1 binding to Pdcd4 was analyzed by western analysis. (D) HEK293 cells were transfected with a plasmid expressing HA-tagged ubiquitin.
Transfected cells were treated for 8 h with DMSO or TPA (10 nM) with or without erioflorin (5 mM) in the presence of the proteasome inhibitor MG132
(10 mg mL
–1). Proteins co-immunoprecipitated with endogenous Pdcd4 and whole-cell extracts were analyzed by western analysis with the indicated
antibodies. All blots are representative for at least three independent experiments.
doi:10.1371/journal.pone.0046567.g003
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(Essen Bioscience) by microscopic determination of monolayer
confluency.
Cell Cycle Analysis
RKO, HeLa and MCF7 cells (1610
5/3 cm-dish) were treated
as indicated. Cells were harvested by centrifugation in PBS, lysed
in PBS
+ (PBS including 1.1 g L
-1 glucose and 0.5 mM EDTA) and
centrifuged again. Pellets were incubated in PBS
+ + RNase (PBS
+
including 50 mgm L
–1 RNase) for 15 min. DNA was stained by
incubation for 15 min with 10% NP-40 and 10 mg propidium
iodide. Stained cells were analyzed using a LSR Fortessa flow
cytometer (BD Bioscience). Cell cycle phase distribution was
calculated with FlowJo software.
Scratch Wound Assay
RKO cells (5610
5/well) were seeded in 24-well plates. Upon
reaching 100% confluency scratches were administered using a
10 mL pipet tip. After removal of medium and floating cells, cells
were treated as indicated and pictures were taken using a Zeiss
microscope Axiovert 200 M. Wound closure was calculated as
scratch width at 24 h relative to initial wound size.
Statistical Analysis
Each experiment was performed at least three times. Repre-
sentative blots are shown. Data are presented as means 6 SEM.
Significance analysis was performed using Student’s t-test.
Figure 4. Erioflorin specifically inhibits E3-ligase b-TrCP1 activity. (A) HEK293 cells were treated with TNFa (20 ng mL
–1) for the indicated
times with or without erioflorin (10 mM). (B) HEK293 cells were maintained under full medium conditions (10% serum) or serum deprived for 24 h
following treatment with erioflorin (5 mM) for 8 h. (C) HEK293 cells were treated for 8 h with erioflorin (1.25–10 mM) or the prolyl-hydroxylase inhibitor
dimethyloxallylglycine (DMOG, 1 mM). (D) HeLa cells were serum deprived for 48 h prior to treatment with erioflorin (10 mM) or the proteasome
inhibitor MG132 (10 mM) for 8 h. Whole cell extracts were subjected to western analysis and probed with the indicated antibodies. Blots are
representative for at least three independent experiments.
doi:10.1371/journal.pone.0046567.g004
Figure 5. Erioflorin inhibits AP-1- and NF-kB-trancriptional activities. (A) HEK293 cells were co-transfected with an AP-1 firefly reporter and a
renilla luciferase plasmid one day prior to experiments. Transfected cells were treated for 16 h with TPA (10 nM) with or without erioflorin (2.5 and
5 mM). Relative AP-1 activity was normalized to renilla luciferase and presented relative to TPA-only treated cells. (B) HEK293 cells were co-transfected
with a NF-kB firefly reporter and a renilla luciferase plasmid one day prior to experiments. Transfected cells were treated for 16 h with TNFa (20 mg
mL
–1) with or without erioflorin (2.5 and 5 mM). Relative NF-kB activity was normalized to renilla luciferase and presented relative to TNFa-only
treated cells. All data are given as means 6 SEM (n$3, **p,0.01).
doi:10.1371/journal.pone.0046567.g005
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PLOS ONE | www.plosone.org 6 October 2012 | Volume 7 | Issue 10 | e46567Figure 6. Erioflorin inhibits cell proliferation and alters cell cycle progression. (A, C, E) MCF7, HeLa and RKO cells were seeded at 10–20%
confluency one day prior to the experiment and treated with DMSO (black diamonds) or erioflorin (2.5 (white triangles) and 5 mM (gray squares)). Cell
confluency was followed for six days. (B, D, F) MCF7, HeLa and RKO cells were serum deprived for 48 h and treated with erioflorin (5 mM) for 16 h.
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Erioflorin Stabilizes Pdcd4 from TPA-Induced
Degradation
We have previously shown that TPA induces the phosphory-
lation-dependent proteasomal degradation of Pdcd4 [5] and
further introduced a luciferase-based assay to identify compounds
stabilizing Pdcd4 from TPA-induced degradation [23,28,29].
Briefly, a vector spanning the domain containing both the
p70
S6K1-phosphorylation and the b-TrCP-recognition motifs (aa
39–91) fused to luciferase (Pdcd4(39–91)luc) served as a sensitive tool
to analyze TPA-induced Pdcd4 degradation. As natural products
provide a rich source for the development of novel therapeutics,
which is supported by the fact that 50% of all small molecule drugs
introduced to the market between 1981 and 2008 (.60% for
cancer therapeutics) were either natural products or derived from
natural products [30], we carried out a high-throughput screen of
135,678 natural product extracts using this approach. We
identified an extract from the woolly sunflower Eriophyllum lanatum
(Asteraceae) to increase the luciferase signal relative to TPA-
treated controls. Sequential fractionation of the extract by solvent
partitioning, size-exclusion chromatography, and C18 HPLC
provided erioflorin as the active agent. Erioflorin is a sesquiterpene
lactone possessing a tricyclic germacranolide skeleton (Figure 1A).
The structure was established by spectroscopic analyses and
comparison of its spectral data with values reported in the
literature. A complete assignment of the
1H NMR data for
erioflorin was made as only a partial assignment has been
published to date [31]. Our data corresponded closely to those
reported for heliangine [32], a structurally related germacranolide
sesquiterpene that only differs from erioflorin by the composition
of the ester side-chain at C-8. The
13C NMR spectral data we
recorded for erioflorin were fully consistent with previously
reported values [33]. The relative configuration of erioflorin was
confirmed by extensive ROESY correlation data.
Dose-response studies revealed that erioflorin significantly
rescued Pdcd4 from 8 h TPA-induced degradation at concentra-
tions as low as 1.25 mM (36.767.5%) (Figure 1B). For a detailed
calculation of the Pdcd4(39–91)luc stabilizing activity see Figure S1A
and B. Maximal recovery of luciferase activity was achieved with
5 mM erioflorin (75.567.4%). At concentrations at or above
10 mM erioflorin luciferase activity was markedly reduced.
HEK293 cells stably expressing the Pdcd4(39–91)luc construct
harboring S67/71/76A mutations (Pdcd4(mut39–91)luc), i.e. an
inactive phospho-degron, which prevents phosphorylation and
degradation, were used to determine nonspecific effects. As no
significant reduction of the luciferase signal in response to TPA-
only treatment in these cells was detected, activity was calculated
relative to TPA-only treated cells (Figure S1C). As shown in
Figure 1C, erioflorin concentrations up to 5 mM, when co-
incubated with TPA, did not affect luciferase activity, whereas
concentrations at or above 10 mM significantly decreased the
luciferase signal. As viability of the cells was not affected at these
concentrations of erioflorin in combination with TPA (Figure
S3A), the loss of luciferase signal was attributed to nonspecific
inhibition of the luciferase vectors. This observation is in
accordance with a previous report showing that other sesquiter-
pene lactones, such as parthenolide, inhibit firefly luciferase activity
[34].
Based on these results, we propose that erioflorin potently
stabilizes Pdcd4(39–91)luc, as an indicator of Pdcd4 protein stability,
from TPA-induced degradation.
Erioflorin Stabilizes Pdcd4 not via p70
S6K1 Inactivation
In line with the concept that TPA-induced degradation of
Pdcd4 requires active PI3K-mTOR-p70
S6K signaling [5,11],
inhibition of p70
S6K [35] or upstream factors such as BCR/ABL
[36] was previously shown to block Pdcd4 degradation. Thus, we
next analyzed the effect of erioflorin on p70
S6K activity. To this
end, HEK293 cells were transiently co-transfected with expression
vectors for wild type p70
S6K (S6Kwt) or a constitutively active
p70
S6K mutant (S6Kca) in combination with either the degradable
Pdcd4(39–91)luc or the stable Pdcd4(mut39–91)luc construct. The
activity of the Pdcd4(mut39–91)luc construct was generally higher
than the activity of the Pdcd4(39–91)luc construct when either
S6Kwt or S6Kca were overexpressed (Figure S2), which verifies
that the intact phospho-degron is required to respond to p70
S6K.
Since p70
S6K1 requires activation by the upstream kinase mTOR,
the mTOR inhibitor rapamycin was expected to affect the activity
of S6Kwt but not of S6Kca. As anticipated, rapamycin (100 nM)
increased Pdcd4(39–91)luc activity significantly more in S6Kwt than
in S6Kca expressing cells. In contrast, erioflorin showed no
significant difference in its ability to stabilize the Pdcd4(39–91)luc
signal under S6Kwt or S6Kca co-expressing conditions (Figure 2A),
which indicates that erioflorin enhances Pdcd4 stability down-
stream of p70
S6K activity. Pdcd4(mut39–91)luc activity was neither
affected by S6Kwt nor by S6Kca and consequently remained
unaffected by treatment with rapamycin or erioflorin (Figure 2B).
These observations serve as a first indication that erioflorin
stabilizes Pdcd4 without interfering with p70
S6K activity that is
required for its phosphorylation.
Erioflorin Protects Endogenous Pdcd4 from TPA-Induced
Degradation
To confirm that erioflorin not only stabilizes Pdcd4(39–91)luc
from TPA-induced degradation but is also effective at the level of
endogenous Pdcd4 protein, we next analyzed Pdcd4 protein
expression upon TPA treatment with or without erioflorin.
Figure 2C (upper panel) shows that Pdcd4 protein was markedly
reduced when HEK293 cells were exposed to TPA (10 nM) for
8 h. Erioflorin rescued Pdcd4 from TPA-induced degradation at
low micromolar concentrations. Quantitative analysis revealed
that Pdcd4 protein was reduced to 49.967.1% of the DMSO
control in response to TPA treatment. Erioflorin rescued Pdcd4
protein expression from TPA-induced loss in a concentration-
dependent manner from 71.164.7% at 0.625 mM to 121.168.6%
at 5 mM as compared to the DMSO control (Figure 2C, middle
panel). Importantly, erioflorin rescued Pdcd4 protein levels from
TPA-induced degradation in the tumor cell lines MCF7 (breast)
and RKO (colon) in a similar fashion (Figure S4). Thus, erioflorin-
mediated Pdcd4 stabilization appears to be a general mechanism
rather than a cell line specific phenomenon. Furthermore,
blocking de novo protein synthesis with cycloheximide (10 mM),
revealed that TPA-restricted Pdcd4 protein half-life (1.260.2 h)
was significantly extended by erioflorin co-treatment (1.960.3 h)
After propidium iodide staining, distribution of the cells to the different phases of the cell cycle (subG1 (white), G1 (light gray), S (dark gray), G2/M
(black)) was determined. (G) RKO colon carcinoma cells were subjected to a scratch wound assay. After administration of the scratch, medium was
changed to control or erioflorin (5 mM) containing medium. Wound closure was measured after 24 h and relative wound closure is given as the ratio
of the width of the scratch at 24 h and to 0 h. All data are given as means 6 SEM (n$3, *p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0046567.g006
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an effect on p70
S6K1 activity, we analyzed phosphorylation of a
prototypical p70
S6K1-target, ribosomal protein S6. While S6-
phosphorylation was increased in response to TPA to
269.9658.4% of the DMSO control, erioflorin did not signifi-
cantly change TPA-induced S6-phosphorylation (Figure 2C,
upper and lower panel).
Taken together, we conclude that erioflorin stabilizes endoge-
nous Pdcd4 from TPA-induced degradation not by interfering
with the phosphorylation of the latter, but rather by mechanisms
affecting the degradation of already phosphorylated Pdcd4.
Erioflorin Disrupts the b-TrCP1/Pdcd4-Interaction
As phosphorylated Pdcd4 is recognized by the E3-ubiquitin
ligase b-TrCP1, which mediates polyubiquitination and subse-
quent proteasomal degradation of its targets [11], we next
determined the effect of erioflorin on the intracellular binding of
b-TrCP1 to Pdcd4. Binding of transiently overexpressed b-TrCP1
to Pdcd4(39–91)luc increased upon treatment with TPA (8 h,
10 nM). Erioflorin (5 mM) significantly diminished the TPA-
induced interaction between Pdcd4(39–91)luc and b-TrCP1
(Figure 3A, right panel). Similarly, b-TrCP1 co-immunoprecipi-
tated with endogenous Pdcd4 in response to TPA (8 h, 10 nM),
which again was significantly attenuated by 5 mM erioflorin
(Figure 3B, right panel). To verify that erioflorin directly targets
the interaction of Pdcd4 with b-TrCP1, we studied the effect of
erioflorin on b-TrCP1-Pdcd4-binding in vitro. As anticipated, in
vitro-transcribed/translated b-TrCP1 bound to in vitro-transcribed/
translated Pdcd4 only in the presence of recombinant p70
S6K.
This binding was markedly reduced in the presence of erioflorin
(Figure 3C). This observation not only supports inhibition of the
interaction between b-TrCP1 and its target Pdcd4 by erioflorin,
but also suggests that inhibition of additional factors within the
proteasomal degradation machinery is not required for erioflorin-
dependent stabilization of Pdcd4. As E3-ligases mediate ubiqui-
tination of interacting target-proteins, we next addressed if
erioflorin affects TPA-induced ubiquitination of Pdcd4. Therefore,
binding of transiently expressed HA-ubiquitin to Pdcd4 was
determined by immunoprecipitation. Indeed, Pdcd4 ubiquitina-
tion in TPA-treated cells (10 nM, 8 h) was reduced dramatically
by co-treatment with erioflorin (5 mM) (Figure 3D).
Taken together, these data indicate that erioflorin stabilizes
Pdcd4 by interfering with the interaction of Pdcd4 with the E3-
ligase b-TrCP1, without affecting Pdcd4 phosphorylation.
Erioflorin Specifically Stabilizes Targets of the E3-Ligase
b-TrCP
In an attempt to gain insights into the selectivity of erioflorin, we
questioned whether erioflorin only interferes with the interaction
between Pdcd4 and b-TrCP or if other b-TrCP targets are
stabilized as well. Among the numerous proteins targeted for
degradation by b-TrCP [37], IkBa is among the best character-
ized ones [38]. When IkBa is phosphorylated by IKKs it is
recognized and bound by b-TRCP and marked for proteasomal
degradation, allowing for activation of the transcription factor NF-
kB [39]. In line, activation of IKKs by TNFa (20 ng mL
–1) led to
the rapid, but transient decrease in IkBa protein levels in HEK293
cells (Figure 4A). Reduced IkBa was observed already after
15 min and was maximal at 30 min of TNFa treatment (lane 3).
Longer treatments with TNFa (60 min) allowed for a complete
recovery of the protein. Erioflorin (10 mM) stabilized IkBa at
30 min of TNFa (compare lanes 1, 3 and 5). Similarly, erioflorin
(8 h, 5 mM) stabilized the b-TrCP-target b-catenin, which is
phosphorylated by the glycogen synthase kinase 3b (GSK3b) [40],
from serum deprivation-induced degradation (Figure 4B). These
results suggest that erioflorin does not interfere exclusively with the
interaction of Pdcd4 and b-TrCP, instead it appears to stabilize
various b-TrCP-targets. We next determined if targets of other E3-
ligases are affected by erioflorin as well. Therefore, we analyzed
the effect of erioflorin on the stability of HIF-1a protein, which is
targeted for proteasomal degradation by the E3-ligase von Hippel-
Lindau protein (pVHL) [41]. Inhibition of the prolyl-hydroxylases,
which mark HIF-1a for interaction with pVHL, using 1 mM
dimethyloxalylglycine (DMOG) for 8 h resulted in strong accu-
mulation of HIF-1a protein (Figure 4C). However, erioflorin (up
to 10 mM) did not stabilize HIF-1a. Along the same line, p21, a
target of the closely related SCF-E3-ligase Skp2 [42], strongly
accumulated when proteasomal degradation was blocked with
MG132 (10 mM) for 8 h whereas it did not increase in response to
erioflorin (5 mM) (Figure 4D). Thus, we propose that erioflorin
stabilizes b-TrCP targets by interfering with the interaction of b-
TrCP1 with them, while leaving targets of other E3-ligases
unaffected. The fact that erioflorin did not stabilize targets of other
E3-ligases can be taken as an indicator that it does not affect
enzymes that would be expected to affect broader target spectra
such as E1- or E2-enzymes. Importantly, further studies are
required to establish the exact site of action of erioflorin, i.e. if it
directly interacts with b-TrCP or rather with phospho-degrons on
the target-proteins.
Taken together, our results imply that erioflorin specifically
inhibits the interaction of the E3-ligase b-TrCP1 with various of its
targets, while it does not affect the stability of proteins regulated by
other E3-ligases. E3-ubiquitin ligases have been increasingly
appreciated as powerful new therapeutic targets in recent years
[43,44]. MLN4924 was identified to inhibit cullin-RING E3-
ubiquitin ligases (CRL) by attenuating the NEDD8-activating
enzyme and thus, preventing neddylation of CRLs [45]. In
addition, various compounds have been identified to inhibit the
activity of or the interaction with targets of specific E3-ligases such
as Skp2 [46], Mdm2 [47], Met30 [48] or Cdc4 [49]. Yet,
erioflorin appears as the first compound interfering with the
degradation of various b-TrCP1 targets such as Pdcd4.
Erioflorin Reduces AP-1- and NF-kB-Dependent
Transcription
As b-TrCP was suggested to be pro-tumorigenic, despite its
broad target-protein spectrum including both pro- (b-catenin) and
anti-oncogenic proteins (Pdcd4, IkBs, BimEL) [37], we next aimed
at determining the functional, tumor-related consequences of
erioflorin. Initially, we analyzed its impact on the activity of the
tumor-associated transcription factors AP-1 and NF-kB. AP-1 was
chosen based on previous reports, which showed that Pdcd4 affects
AP-1 activity [24,50], while NF-kB was selected since it is the
direct target of the above analyzed IkBa [39]. To this end,
HEK293 cells were transiently transfected with an AP-1 reporter
vector one day prior to the experiment. Treatment with TPA
(10 nM, 16 h) strongly induced AP-1 activity. Erioflorin reduced
TPA-induced AP-1 activity to 74.669.7% at 2.5 mM and to
51.766.2% at 5 mM (Figure 5A). This effect was not due to
toxicity as TPA in combination with erioflorin (up to 20 mM) was
not toxic in this setting (Figure S3A). To assess the impact of
erioflorin on NF-kB activity, HEK293 cells were transiently
transfected with a NF-kB reporter vector one day prior to the
experiment. Treatment with TNFa (20 ng mL
–1, 16 h) strongly
induced NF-kB activity. While erioflorin co-treatment only slightly
inhibited TNFa-induced NF-kB activity at 2.5 mM, 5 mM
erioflorin sufficed to significantly reduce the activity to
55.766.3% of TNFa-only treated cells (Figure 5B). Again,
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adversely affect cell viability in these cells (Figure S3B).
These results imply that erioflorin not only stabilizes b-TrCP-
target-proteins, but also inhibits transcriptional activity of down-
stream effectors such as AP-1 and NF-kB.
Erioflorin Shows Anti-Proliferative Potential In Vitro
Both AP-1 and NF-kB have been extensively shown to play an
important role in tumorigenesis and tumor cell proliferation.
Therefore, we next addressed the influence of erioflorin on the
proliferation of various cancer cell lines. Erioflorin treatment (2.5
and 5 mM) reduced proliferation of MCF7 (weakly), HeLa
(moderately-strongly) and RKO cells (strongly) (Figure 6A, C,
E). This is in line with a recent report demonstrating that
inhibition of b-TrCP by genetic means attenuated viability and
proliferation of breast cancer cells and rendered them more
sensitive to various anticancer drugs [18]. Interestingly, cell cycle
analysis revealed that, while MCF7 cells showed only minor
changes in cell cycle distribution in response to erioflorin (5 mM),
both HeLa and RKO cells displayed a pronounced increase in
G2/M- and subG1-phases, whereas G1- and S-phases were
reduced (Figure 6B, D, F and Table S1). These findings closely
correlate with our observations on proliferation, where MCF7 cells
also appeared to be least sensitive. Interestingly, while the increase
in sub-G1, i.e. apoptosis, in the tumor cell lines (RKO.He-
La.MCF7) in response to erioflorin appears to contradict
previous observations that the viability of HEK293 cells was not
affected by erioflorin (Figure S3), this might be due to different
experimental conditions and/or cell types. Specifically, the lack of
toxicity in HEK293 cells fits well with the observed sequence of
sensitivities, i.e. more advanced tumor cells (e.g. RKO) being more
sensitive to erioflorin than non-invasive tumor cells (e.g. MCF7) or
non-tumorigenic cells (e.g. HEK293). Therefore, we lastly
performed scratch wound assays using the highly invasive, yet
most erioflorin-sensitive colon carcinoma cell line RKO. RKO
cells efficiently closed (90.965.2%) scratches in confluent cell
layers at 24 h, whereas erioflorin (5 mM) significantly inhibited
wound closure to 53.8611.0% (Figure 6G). These observations
further strengthen the notion that disrupting the interaction
between b-TrCP and its targets could open a novel avenue for the
development of future anti-cancer therapeutics.
In summary, these data show that erioflorin suppresses tumor-
associated events such as activation of AP-1- and NF-kB-
dependent transcription and in addition alters cell cycle progres-
sion resulting in inhibition of proliferation in tumor cells.
Interestingly, erioflorin appears to affect proliferation and cell
cycle progression preferentially in more advanced tumor cell lines
as compared to non-invasive lines or non-tumorigenic lines, which
might be interest with respect to the development of future tumor
therapeutics targeting b-TrCP.
Conclusion
This is the first report characterizing a natural product, small
molecule compound that tumor suppressor Pdcd4 by interrupting
its interaction with the E3-ligase b-TrCP. As erioflorin selectively
stabilizes a number of b-TrCP targets leaving targets of other E3-
ligases unaffected, it appears to functionally work as a b-TrCP
inhibitor. We further provide evidence that erioflorin holds anti-
tumorigenic potential as it inhibits AP-1 and NF-kB transcrip-
tional activity, and interferes with cell cycle progression and
proliferation of tumor cells. Based on the distinct set of proteins
targeted by b-TrCP1 for degradation, we predict that erioflorin
will generate less adverse side effects as compared to general
proteasome inhibitors currently used in tumor therapy.
Supporting Information
Figure S1 Conversion of relative Pdcd4(39–91)luciferase
light units to relative Pdcd4(39–91) stabilizing activity. (A)
Stably Pdcd4(39–91)luc expressing HEK293 cells were treated for
8 h with TPA (10 nM) with or without rapamycin (100 nM).
Relative light units (RLU) of the Pdcd4(39–91)luciferase fusion
protein were normalized to DMSO. (B) Experiment from (A).
Pdcd4(39–91) stabilizing activity of rapamycin was determined
relative to D(RLUcontrol–RLUTPA-only). (C) Stably Pdcd4(mut39–
91)luc expressing HEK293 cells were treated as in (A). Luciferase
activity is given relative to TPA-treated controls.
(DOC)
Figure S2 Expression of Pdcd4(39–91)luc and Pdcd4(mut39–
91)luc in the presence of overexpressed p70
S6K. HEK293
cells were transiently transfected with Pdcd4(39–91)luc (left bars) or
Pdcd4(mut39–91)luc (right bars) firefly reporter vectors, in combina-
tion with expression vectors for either wildtype (S6Kwt=white
bars) or constitutively active p70
S6K (S6Kca=black bars) and a
renilla luciferase vector one day prior to the experiment. Firefly
luciferase levels were normalized to renilla luciferase and presented
relative to Pdcd4(39–91)luc/S6Kwt (relative light units=RLU).
(DOC)
Figure S3 Erioflorin does not influence cell viability in
combination with TPA or TNFa. (A) HEK293 cells were
treated for 16 h with TPA (10 nM) with or without erioflorin (2.5
to 20 mM). Cell viability was analyzed using the CellTiter glow
assay (Promega) according to manufacturer’s protocol and is given
relative to DMSO-treated controls. (B) HEK293 cells were treated
for 16 h with TNFa (20 ng mL
–1) or with or without erioflorin (2.5
and 5 mM). Cell viability was analyzed as described in A.
(DOC)
Figure S4 Erioflorin stabilizes Pdcd4 in breast and
colon carcinoma cells. (A) MCF7 and (B) RKO cells were
treated for 8 h with TPA (10 nM) with or without erioflorin
(10 mM). Whole-cell extracts were subjected to Western analysis
and probed with the indicated antibodies.
(DOCX)
Table S1 Cell cycle distribution in response to erioflorin.
(DOC)
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